Dipti Patel‐Donnelly

Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma

Sven de Vos, André Goy, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2009 · 94 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin et al. · Leukemia · 2014 · 76 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

James R. Berenson, Ori Yellin, Alberto Bessudo et al. · British Journal of Haematology · 2012 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +16

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

David Andorsky, Kathryn S. Kolibaba, Sarit Assouline et al. · British Journal of Haematology · 2018 · 47 citations · Full text

Medicine, Hematology, Oncology +17

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

John M. Burke, Andrei R. Shustov, James Essell et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +14